Treatment of AML in biological subgroups

被引：3

作者：

Buechner, T

Berdel, WE

Schoch, C

Haferlach, T

Serve, HL

Schnittger, S

Kern, W

Tchinda, J

Reichle, A

Staib, P

Ludwig, WD

Aul, C

Sauerland, MC

Heinecke, A

Woermann, B

Hiddemann, W

机构：

[1] Univ Munster, Ctr Med, Dept Med Hematol Oncol, D-48129 Munster, Germany

[2] Univ Munster, Ctr Med, Dept Human Genet, D-48129 Munster, Germany

[3] Univ Munster, Ctr Med, Dept Med Informat & Biomath, D-48129 Munster, Germany

[4] Univ Regensburg, Ctr Med, Dept Hematol & Oncol, D-8400 Regensburg, Germany

[5] Univ Cologne, Ctr Med, Dept Hematol & Oncol, Cologne, Germany

[6] Univ Berlin, Ctr Med, Dept Hematol & Oncol, Berlin, Germany

[7] St Johannes Hosp, Dept Hematol & Oncol, Duisburg, Germany

[8] Municipal Med Ctr, Dept Hematol & Oncol, Braunschweig, Germany

[9] Univ Munich, Dept Internal Med 3, D-80539 Munich, Germany

来源：

HEMATOLOGY | 2005年 / 10卷

关键词：

D O I：

10.1080/10245330512331390212

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

[No abstract available]

引用

页码：281 / 285

页数：5

共 30 条

[1]

BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics:: a Cancer and Leukemia Group B Study [J].

Baldus, CD ;

Tanner, SM ;

Ruppert, AS ;

Whitman, SP ;

Archer, KJ ;

Marcucci, G ;

Caligiuri, MA ;

Carroll, AJ ;

Vardiman, JW ;

Powell, BL ;

Allen, SL ;

Moore, JO ;

Larson, RA ;

Kolitz, JE ;

de la Chapelle, A ;

Bloomfield, CD .

BLOOD, 2003, 102 (05) :1613-1618

[2]

Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia [J].

Bertz, H ;

Potthoff, K ;

Finke, J .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) :1480-1484

[3]

Bloomfield CD, 1998, CANCER RES, V58, P4173

[4]

Büchner T, 1999, BLOOD, V93, P4116

[5]

Buchner T, 2005, J CLIN ONCOL, V23, p573S

[6]

6-thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML):: A randomized trial of the German AML cooperative group [J].

Büchner, T ;

Hiddemann, W ;

Berdel, WE ;

Wörmann, B ;

Schoch, C ;

Fonatsch, C ;

Löffler, H ;

Haferlach, T ;

Ludwig, WD ;

Maschmeyer, G ;

Staib, P ;

Aul, C ;

Grüneisen, A ;

Lengfelder, E ;

Frickhofen, N ;

Kern, W ;

Serve, HL ;

Mesters, RM ;

Sauerland, MC ;

Heinecke, A .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) :4496-4504

[7]

BUCHNER T, IN PRESS CRIT REVI O

[8]

Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial [J].

Burnett, AK ;

Goldstone, AH ;

Stevens, RMF ;

Hann, IM ;

Rees, JKH ;

Gray, RG ;

Wheatley, K .

LANCET, 1998, 351 (9104) :700-708

[9]

Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered [J].

Byrd, JC ;

Dodge, RK ;

Carroll, A ;

Baer, MR ;

Edwards, C ;

Stamberg, J ;

Qumsiyeh, M ;

Moore, JO ;

Mayer, RJ ;

Davey, F ;

Schiffer, CA ;

Bloomfield, CD .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (12) :3767-3775

[10]

Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22):: Results from CALGB 8461 [J].

Byrd, JC ;

Ruppert, AS ;

Mrózek, K ;

Carroll, AJ ;

Edwards, CG ;

Arthur, DC ;

Pettenatti, MJ ;

Stamberg, J ;

Koduru, PRK ;

Moore, JO ;

Mayer, RJ ;

Davey, FR ;

Larson, RA ;

Bloomfield, CD .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) :1087-1094

← 1 2 3 →